No Ace For J&J’s VENTURA Studies Of Aticaprant In Depression

 
• By Alexandra Shimmings

The future of kappa opioid receptor antagonism as a therapeutic strategy in major depressive disorder is looking increasingly bleak after J&J dropped aticaprant from development, but rival Neumora is pressing on with navacaprant.

Depression concept
(Shutterstock)

More from Clinical Trials

More from Therapy Areas